Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Open Label Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and GEJ Cancer

NCT04467515 is registered in ClinicalTrials.gov with Precirix as lead sponsor.

NCT NCT04467515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04467515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Open Label Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and GEJ Cancer
Lead sponsor
Precirix
Phase
Phase 1/2
Overall status
Terminated
Start date
September 14, 2021
Completion date
December 11, 2023
Enrollment
13 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic her2-positive breast, gastric, gastroesophageal junction cancer with disease progression following anti-her2 standard of care treatment